Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Solid Tumor, Adult
Clinical trial register · United States · industry-sponsored

Solid Tumor, Adult Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9141 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 18 Oct 2026, 03:16 UTC
9141
Studies in scope
industry-sponsored, all four open statuses
4966
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 30 Florida 20 New York 19 Texas 17 Massachusetts 13
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
A2 Biotherapeutics Inc.4 CytomX Therapeutics2 Verastem, Inc.1 Krystal Biotech, Inc.1 BioEclipse Therapeutics1
State
California30 Florida20 New York19 Texas17 Massachusetts13
All 34 states
Target enrolment
to

Solid Tumor, Adult trials in the USA

39 of 9141 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
HMPL-A830 in Solid Tumors
NCT07718581Solid Tumor, Adult
Hutchmed
Phase 1/2
147
California, Florida, New Jersey, Tennessee, Utah
2026-09-24
Recruiting
Rise Therapeutics LLC
Phase 1
33
Colorado, Tennessee
2025-08-01
Recruiting
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult
DrugsRepaglinide·VS-7375·Defactinib·Erbitux
Verastem, Inc.
Phase 1/2
616
California, Maryland, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Tennessee
2025-06-24
Recruiting
A2 Biotherapeutics Inc.
Phase 1/2
240
Arizona, California, Florida, Minnesota, Missouri, New York, Ohio, Washington
2025-05-22
Recruiting
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
NCT06915753Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification
Tyra Biosciences, Inc
Phase 1
125
California, Kansas, Maryland, Massachusetts, Michigan, New York, Tennessee
2025-04-24
Recruiting
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT06625775Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors
DrugsBBO-10203·Ribociclib·Folfox·Fulvestrant
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
392
California, Florida, Indiana, Massachusetts, Missouri, New York, Tennessee, Texas
2024-10-29
Recruiting
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
NCT06598007Solid Tumor, Adult, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
DrugFolfox
Crossignal Therapeutics, Inc.
Phase 1/2
78
Texas
2024-09-20
Recruiting
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT06586957Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor
DrugsDoxorubicin·Paclitaxel
NiKang Therapeutics, Inc.
Phase 1
238
Arkansas, California, Colorado, Florida, Georgia, Kansas, Massachusetts, New Jersey
2024-09-19
Recruiting
A Study of VET3-TGI in Patients With Solid Tumors
NCT06444815Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer
DrugAtezolizumab
KaliVir Immunotherapeutics
Phase 1
60
California, Florida, Indiana, Pennsylvania, Texas
2024-09-16
Recruiting
DualityBio Inc.
Phase 1/2
360
California, District of Columbia, Florida, Illinois, North Carolina, Pennsylvania, Tennessee, Utah
2024-09-03
Recruiting
CytomX Therapeutics
Phase 1
121
California, Colorado, Pennsylvania, Tennessee, Texas
2024-08-28
Active, closed
Kumquat Biosciences Inc.
Phase 1
92
Colorado, Florida, Michigan, New York, Ohio, Tennessee, Texas, Virginia
2024-06-03
Recruiting
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
NCT06228326Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer
DrugsKB707·Docetaxel·Keytruda·Pembrolizumab
Krystal Biotech, Inc.
Phase 1/2
250
Alabama, Arizona, California, Florida, Indiana, Louisiana, Michigan, Ohio
2024-04-17
Recruiting
A2 Biotherapeutics Inc.
Phase 1/2
474
Arizona, California, Florida, Minnesota, Missouri, New York, Ohio, Tennessee
2024-04-03
Recruiting
CytomX Therapeutics
Phase 1
160
Colorado, Massachusetts, New York, North Carolina, Tennessee, Texas, Virginia
2024-04-02
Recruiting
Corbus Pharmaceuticals Inc.
Phase 1/2
348
Alabama, California, Colorado, Connecticut, Florida, Illinois, Massachusetts, Nebraska
2024-04-01
Recruiting
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
NCT06244771Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor
Frontier Medicines Corporation
Phase 1/2
403
California, Florida, Indiana, Kansas, Massachusetts, Michigan, Pennsylvania, Texas
2024-02-12
Active, closed
ImmuneSensor Therapeutics Inc.
Phase 1
2
Arizona, California
2023-09-15
Active, closed
A2 Biotherapeutics Inc.
Phase 1/2
160
Arizona, California, Florida, Minnesota, Missouri, New York, Texas
2023-04-28
Recruiting
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
NCT05856981Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer, CRC, Colorectal Cancer
DrugsKeytruda·Pembrolizumab
Sairopa B.V.
Phase 1
130
Michigan, Missouri, Ohio, Virginia
2023-04-03
Recruiting
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
NCT05669430Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
DrugsGV20-0251·Keytruda·Pembrolizumab
GV20 Therapeutics
Phase 1/2
365
California, Colorado, Connecticut, Florida, Indiana, Massachusetts, Michigan, New York
2023-03-23
Active, closed
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
NCT05662397Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer
DrugCemiplimab
HotSpot Therapeutics, Inc
Phase 1/2
77
Florida, Nevada, New York, Oregon, Pennsylvania, Texas
2023-03-15
Active, closed
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
NCT05651022Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma
DrugTislelizumab
Indaptus Therapeutics, Inc
Phase 1/2
120
California, Georgia, Michigan, Missouri, New Jersey, New York, Ohio, Pennsylvania
2023-02-28
Recruiting
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
NCT04196257Solid Tumor, Adult, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Endometrial Cancer
Bio-Path Holdings, Inc.
Phase 1
50
Maryland, Michigan, Texas
2022-08-19
Recruiting
Relay Therapeutics, Inc.
Phase 1
930
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Massachusetts
2021-12-08
Recruiting
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
NCT04981119Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer
A2 Biotherapeutics Inc.
Observational
500
Arizona, California, Florida, Massachusetts, Minnesota, Missouri, New York, Ohio
2021-10-29
Recruiting
Trethera
Phase 1
94
California, North Carolina
2021-09-23
Recruiting
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
NCT04913285Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Pierre Fabre Medicament
Phase 1
400
California, Colorado, Florida, Minnesota, New Jersey, New York, Ohio, Tennessee
2021-08-04
Active, closed
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
NCT04673942Solid Tumor, Adult, Cancer, Neoplasms, Sarcoma
EpicentRx, Inc.
Phase 2
140
California, Ohio, Texas
2021-03-29
Recruiting
Vivace Therapeutics, Inc
Phase 1/2
434
California, Illinois, Massachusetts, Minnesota, New York, Texas, Virginia
2021-03-24
Recruiting
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
NCT04282044Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma
BioEclipse Therapeutics
Phase 1
60
Arizona, California
2021-01-08
Active, closed
Study to Evaluate D-1553 in Subjects With Solid Tumors
NCT04585035Solid Tumor, Adult, NSCLC, CRC
DrugD-1553
InventisBio Co., Ltd
Phase 1/2
180
California, Kentucky, Michigan, New York, Oregon
2020-10-02
Recruiting
BioInvent International AB
Phase 1/2
197
California, Colorado, Minnesota, Oklahoma, Texas
2020-06-29
Recruiting
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1
78
Indiana, Texas
2020-06-26
Active, closed
First-in-Human Study of ICT01 in Patients With Advanced Cancer
NCT04243499Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer
ImCheck Therapeutics, an Ipsen company
Phase 1/2
293
Arizona, California, Connecticut, Florida, New York, Texas, Washington
2020-03-05
Active, closed
Linnaeus Therapeutics, Inc.
Phase 1/2
200
California, Connecticut, Massachusetts, New Mexico, New York, Pennsylvania, Texas
2019-10-21
Active, closed
Nouscom SRL
Phase 1/2
115
California, Florida, Indiana, Maryland, Missouri, New York, Texas
2019-10-21
Recruiting
Immatics US, Inc.
Phase 1/2
375
California, Colorado, Florida, Illinois, Massachusetts, New York, Ohio, Pennsylvania
2019-05-14
Recruiting
BioCytics, Inc.
Observational
1,500
North Carolina
2007-11
Rows per page Showing 1–39 of 39
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 18 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/solid-tumor-adult

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,141 studies in total at the last sync on 18 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 39 of those studies listing the condition Solid Tumor, Adult.

How many Solid Tumor, Adult trials are recruiting in the US?

29 of the 39 studies on this page are recruiting new participants as of the 18 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Solid Tumor, Adult), 39 studies
PhaseStudiesRecruitingShare
Phase 1/2201351.3%
Phase 1161441%
Observational225.1%
Phase 2102.6%

Most active sponsors

Lead sponsors with the most studies (Solid Tumor, Adult)
Lead sponsorStudiesRecruiting
A2 Biotherapeutics Inc.43
CytomX Therapeutics22
Bio-Path Holdings, Inc.11
BioCytics, Inc.11
BioEclipse Therapeutics11
BioInvent International AB11
Corbus Pharmaceuticals Inc.11
Crossignal Therapeutics, Inc.11
DualityBio Inc.11
EpicentRx, Inc.10

Top states

Top states (Solid Tumor, Adult), by number of studies with a site there
StateStudies
California30
Florida20
New York19
Texas17
Massachusetts13
Colorado11
Tennessee11
Michigan10
Ohio10
Arizona9
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.